An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2017
At a glance
- Drugs M 4344 (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono Research & Development Institute; Vertex Pharmaceuticals
- 03 Nov 2017 Planned End Date changed from 1 Nov 2018 to 26 May 2019.
- 03 Nov 2017 Planned primary completion date changed from 1 Nov 2018 to 25 Dec 2018.
- 01 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Nov 2018.